Telehealth company Favor to offer new FDA-approved hormone-free contraceptive

The telehealth company Favor has become a specialty pharmacy provider of Evofem Biosciences’ hormone-free contraceptive gel.

The company’s first FDA-approved product is a hormone-free, on-demand prescription contraceptive vaginal gel and comes in an applicator that is used similarly to a tampon.

Women will be able to order it through Favor’s platform where they will also be counselled prior to the prescription.

Evofem, the company behind Phexxi, aims to develop innovative products to address unmet needs in women’s sexual and reproductive health and expects the collaboration with Favor will begin contributing to retail channel growth in 2023.

Saundra Pelletier, Evofem CEO, said: “We are delighted that Favor is expanding its portfolio to offer its patients a non-hormonal contraceptive.

“Phexxi appeals to a wide variety of women who seek hormone-free contraception, whether by need or by choice, offering them a safe and effective, FDA-approved contraceptive method that they control and use only when they need it.”

Liz Meyerdirk, Favor CEO, added: “We are proud to offer Phexxi for women and people who menstruate seeking non-hormonal contraceptive options.

“Hormonal contraceptives aren’t for everyone; in fact, thousands of patients come to Favor every year who need a non-hormonal birth control method, and I’m thrilled that we can now deliver a trusted option right to their doorstep.”

Favor’s digital healthcare platform combines telemedicine and direct-to-consumer pharmacy and aims to give women access to affordable birth control, skin care and menstrual care.